ClinicaliQ Trial Snapshot
- A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) — Recruiting • Phase II / Phase III • NCT07159841.
- A trial testing whether a new drug (atumelnant) safely and effectively treats congenital adrenal hyperplasia in children.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participants with classic congenital adrenal hyperplasia (CAH). Conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia Interventions: Atumelnant, Placebo Lead Sponsor: Crinetics Pharmaceuticals Inc. Planned Enrollment: 153 participants